Navigation Links
InterMune Announces Pricing of $68 Million Public Offering of Common Stock
Date:9/21/2007

BRISBANE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the pricing of its underwritten public offering of 3,500,000 shares of newly issued common stock at a price to the public of $19.50 per share. InterMune also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock. All of the shares in the offering are being sold by InterMune.

Goldman, Sachs & Co. is acting as the sole book-running manager of the offering. Deutsche Bank Securities Inc. is acting as co-lead manager and CIBC World Markets Corp. is acting as co-manager of the offering.

These shares are being issued pursuant to an effective shelf registration statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Printed copies of the final prospectus supplement and base prospectus relating to the offering may be obtained, when available, from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com). InterMune intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the base prospectus filed with the SEC in connection with the shelf registration on the SEC's website at

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., a ... drugs for diseases of the central nervous system, today ... chief executive officer, will present at the 33 rd ... will take place at 3:00 p.m. PST on Tuesday, ... San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that ... SL-501, in both in vitro and animal models of ... at the upcoming 51st Annual Meeting of the American Society of ... 2009. The poster will be presented by Stemline,s collaborators at The ...
... MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator ... signed a licensing agreement with Harvard University granting Nikon ... (STORM) technology. Under the terms of the agreement, Nikon ... with the N-STORM name. , Nikon Corporation President, ...
... , PHILADELPHIA, Dec. 3 Shire plc ... company, today announced a voluntary recall of five lots and ... (ADHD) patch Daytrana ® . Shire is taking this action ... future may not meet their release liner removal specification, and ...
Cached Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 2010 Microbiologists at UT Southwestern Medical Center, working with ... cattle that could be exploited to help prevent outbreaks of ... coli . In the study, available online and ... National Academy of Sciences , researchers interfered with a genetic ...
... better mental health than British Whites, new research from ... Anna Goodman, the report,s lead author from London ... into ethnic differences focuses on issues where minority ethnic ... it is also important to investigate areas where minority ...
... release is available in Spanish . The study ... of nursing mothers did not follow a proper diet, as they ... E and iron, and the intake of proteins was too high. ... increase nutritional supply to the newborn. This study was conducted ...
Cached Biology News:UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle 2British Indian children have better mental health 2About 94 percent of breastfeeding mothers do not follow a proper diet 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Biology Products: